|
STIRIPENTOL
 INN STIRIPENTOL
|
cas 137767-55-6 |
CLASS NERVOUS SYSTEM TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM THE MECHANISM OF ACTION IS UNKNOWN |
|
ATC code
N03AX17 |
PK parameters Tmax 2.5 HOUR PPB 99 PERCENT t1/2 8.7 HOUR
SolubilityPRACTICALLY INSOLUBLE IN WATER
|
Target - |
DrugCentral Unknown |
Download SDF file |
1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-, (1E)- Formula: C14H18O3 Calculated chemical properties: MW 234.28 NB_atoms 17 XLogP 2.84 PSA 41.781 NB_HD 1 NB_HA 3 fsp3 0.43 Lipinski(0=no;1=yes) 1 |
FDA NDA 206709 (pdf not found) INN (STIRIPENTOL) DIACOMIT (BIOCODEX SA) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY NDA 207223 (pdf not found) INN (STIRIPENTOL) DIACOMIT (BIOCODEX SA) APPROVAL= AP YEAR= 2018 |
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |